Harnessing the power of the human microbiome to prevent and treat disease.
We are leveraging the untapped potential of the human microbiome to develop novel medicinal products that restore health and prevent disease, with a specific focus on drug-resistant bacterial infections.
Find out more
Expanding access to Faecal Microbiota Transplantation (FMT) internationally.
We manufacture rigorously screened, off-the-shelf and ready-to-use microbial preparations that can be distributed to clinicians on a named patient basis under a license from the MHRA. 
Find out more
Pioneering an entirely new class of medicinal product to tackle antibiotic resistance.
We are developing and advancing exciting new therapies composed of live microorganisms and highly engineered precision antimicrobials.
Find out more

Harnessing the power of the human microbiome to prevent and treat disease.

We are leveraging the untapped potential of the human microbiome to develop novel medicinal products that restore health and prevent disease, with a specific focus on drug-resistant bacterial infections.

Your Microbiome

The human microbiome is composed of over a trillion microorganisms that play a key role in many critical bodily functions. Many believe that the microbiome has substantial untapped therapeutic potential. At EnteroBiotix, we are unlocking this potential through novel approaches to treat disease and improve human health.

Our Company

We are developing and advancing novel microbiome modulating drugs composed of bacterial communities derived directly from the healthy human gastrointestinal tract. We have established field leading capabilities, a seasoned team, and a substantial number of high-profile partnerships to support us on our mission.

Our Approach

We are leveraging our MHRA-licensed platform capabilities, know-how and proprietary technology to advance three core product portfolios that build on the science of a medical treatment called faecal microbiota transplantation (FMT). Our initial focus is on antibiotic-resistant bacteria.

For patients

If you’re a patient suffering from an infection caused by C.difficile or a different type of microbiome mediated condition, you may be able to access our products through your doctor and our compassionate use programme.

For clinicians

We have rigorously screened and ready-to-use microbial products manufactured under a license from the MHRA. These products are available to order on a named patient basis for use in FMT.